Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.

Literature DB >> 18685916

Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.

Verena I Leussink, Helmar C Lehmann, Gerd Meyer zu Hörste, Hans-Peter Hartung, Olaf Stüve, Bernd C Kieseier.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18685916 DOI： 10.1007/s00415-008-0956-x

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

13 in total

1. Natalizumab effects on immune cell responses in multiple sclerosis.

Authors: Masaaki Niino; Caroline Bodner; Marie-Lune Simard; Sudabeh Alatab; Dawn Gano; Ho Jin Kim; Manuela Trigueiro; Denise Racicot; Christine Guérette; Jack P Antel; Alyson Fournier; Francois Grand'Maison; Amit Bar-Or
Journal: Ann Neurol Date: 2006-05 Impact factor: 10.422

2. The B cell--old player, new position on the team.

Authors: Henry F McFarland
Journal: N Engl J Med Date: 2008-02-14 Impact factor: 91.245

3. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

Authors: Nancy L Monson; Petra D Cravens; Elliot M Frohman; Kathleen Hawker; Michael K Racke
Journal: Arch Neurol Date: 2005-02

4. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

Authors: Mark Keegan; Fatima König; Robyn McClelland; Wolfgang Brück; Yazmín Morales; Andreas Bitsch; Hillel Panitch; Hans Lassmann; Brian Weinshenker; Moses Rodriguez; Joseph Parisi; Claudia F Lucchinetti
Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321

5. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Authors: Olaf Stüve; Sabine Cepok; Birte Elias; Andreas Saleh; Hans-Peter Hartung; Bernhard Hemmer; Bernd C Kieseier
Journal: Arch Neurol Date: 2005-10

6. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Authors: Anne H Cross; Jennifer L Stark; Joanne Lauber; Michael J Ramsbottom; Jeri-Anne Lyons
Journal: J Neuroimmunol Date: 2006-08-14 Impact factor: 3.478

Review 7. Multiple sclerosis: a complicated picture of autoimmunity.

Authors: Henry F McFarland; Roland Martin
Journal: Nat Immunol Date: 2007-09 Impact factor: 25.606

8. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors: Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal: N Engl J Med Date: 2008-02-14 Impact factor: 91.245

9. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors: Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245

10. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245

8 in total

1. Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors: Mixalis L Kosmidis; Marinos C Dalakas
Journal: Ther Adv Neurol Disord Date: 2010-03 Impact factor: 6.570

2. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

Authors: Elizabeth M Cameron; Sade Spencer; Jonathan Lazarini; Christopher T Harp; E Sally Ward; Mark Burgoon; Gregory P Owens; Michael K Racke; Jeffrey L Bennett; Elliot M Frohman; Nancy L Monson
Journal: J Neuroimmunol Date: 2009-07-24 Impact factor: 3.478

Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.

1. Natalizumab effects on immune cell responses in multiple sclerosis.

2. The B cell--old player, new position on the team.

3. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

4. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

5. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

6. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Review 7. Multiple sclerosis: a complicated picture of autoimmunity.

8. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

9. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

10. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

1. Practical considerations on the use of rituximab in autoimmune neurological disorders.

2. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

Review 3. Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

4. Language impairment and right hemiparesis in a 54-year-old woman.

Review 5. Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis.

6. Refractory Fulminant Acute Disseminated Encephalomyelitis (ADEM) in an Adult.

Review 7. [Ocrelizumab for treatment of multiple sclerosis].

Review 8. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.